Trial document




This trial has been registered retrospectively.
drksid header

  DRKS00012759

Trial Description

start of 1:1-Block title

Title

Investigating the German response scale of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) – a three-step approach

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

EORTC Response Scale

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The original EORTC questionnaire assess the quality of life of patients with cancer. The questionnaie was developed in English, and other language versions, including German, were created in parallel. With exception of two items, all items of the actual Version are scored on a 4-point Likert scale: 1 “not at all”, 2 “a little”, 3 “quite a bit”, and 4 “very much”. The German equivalents have been translated as 1 “überhaupt nicht”, 2 “wenig”, 3 “mäßig”, and 4 “sehr”.

The German term "mäßig" is close to the term "wenig", thus violating the interval properties of the scale. The present project will investigate whether the "mäßig" should be replaced by another term and whether this improves the measurement properties of the scale.

Patients participating in this study will fill in the questionnaire twice, once in the conventional design ("mäßig") and once in the updated design with the response alternative "ziemlich". The order of the questionnaire designs and the presentation modes (paper/pencil versus computer) will be randomized.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

The original EORTC questionnaire was formulated in English, and other language versions, including German, were created in parallel. With exception of two items, all items of the actual Version are scored on a 4-point Likert scale: 1 “not at all”, 2 “a little”, 3 “quite a bit”, and 4 “very much”. The German equivalents have been translated as 1 “überhaupt nicht”, 2 “wenig”, 3 “mäßig”, and 4 “sehr”.

The German term "mäßig" is close to the term "wenig", thus violating the interval properties of the scale. The present project will investigate whether the "mäßig" should be replaced by another term and whether this improves the measurement properties of the scale.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

[---]*

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00012759
  •   2017/08/04
  •   [---]*
  •   yes
  •   Approved
  •   14-101-0209, Ethikkommission an der Universität Regensburg
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   Z-2014-0368-2  (Zentrum für Klinische Studien Regensburg)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Adaption of the German version of the questionnaire for cancer patients EORTC QLQ-C30
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Step I investigates the properties of the critical response term “mäßig” and its alternatives.
  •   Step II refers to the development of an updated German EORTC QLQ-C30 version with an improved response scale.
  •   Step III: Both questionnaires, conventional and updated, are available in a paper/pencil and a table version. Each patient fills in 2 qestionnaires and their assignment is randomized.

    Arm 3: conventional questionnaire/paper version
  •   Step III: updated questionnaire/paper version
  •   Step III: conventional questionnaire/tablet version
  •   Step III: updated questionnaire/tablet version
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Observational study
  •   Randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Other
  •   Other
  •   Other
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

The primary endpoint is the score of the EORTC QLQ-C30 as calculated according to the scoring manual. The score will be calculated twice, with regard to the the first and the second assessment. The critical value of interest is the difference between scores of the conventional and the updated version. This difference will be assessed in the between (group comparisons) and within (before-after effects) conditions.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

[---]*

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
  •   Switzerland
  •   Austria
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
  • University Medical Center 
  • Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2016/04/01
  •   500
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Cancer, informed consent, ability to fill in a questionnaire

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

[---]*

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Universitätsklinikum RegensburgZentrum für Klinische Studien
    • Mr.  Prof. Dr.  Michael  Koller 
    • Franz-Josef-Strauss-Allee 11
    • 9053  Regensburg
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Universitätsklinikum RegensburgZentrum für Klinische Studien
    • Mr.  Prof. Dr.  Michael  Koller 
    • Franz-Josef-Strauss-Allee 11
    • 9053  Regensburg
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Universitätsklinikum RegensburgZentrum für Klinische Studien
    • Mr.  Prof. Dr.  Michael  Koller 
    • Franz-Josef-Strauss-Allee 11
    • 9053  Regensburg
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • European Organisation for Research and Treatment of Cancer
    • Av. E. Mounierlaan 83
    • 1200  Brüssel
    • Belgium
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.